Mauro Ferrari, PhD, president of the Houston Methodist Institute for Academic Medicine and chief commercialization officer, has retired from Houston Methodist to pursue other opportunities in research, education and service to the underprivileged.
Ferrari served in his leadership roles for the past eight years and brought national acclaim to our research institute. Under his leadership, we recruited some of the world’s most preeminent scientists and conducted impactful research that will change patients’ lives. We appreciate his commitment to building the RI and his dedication to take our research from the bench to the bedside as quickly as possible. Ferrari was recently made chief commercialization officer to further fulfill our promise of a more rapid discovery process by creating a virtuous cycle of funding for additional discovery.
Ferrari is considered a pioneer of biomedical nano/micro-technology, especially as they relate to drug delivery, cell transplantation and implantable bioreactors. He has to his credit more than 450 publications, including seven books and is the inventor of 46 issued patents in the U.S. and Europe. He was a principal investigator on multiple large grants from the National Cancer Institute and the Department of Defense.
His contributions to the field of biomedical nanotechnology have been recognized through numerous awards and accolades, including: Founders Award − Controlled Release Society, the Wallace H. Coulter Award for Biomedical Innovation and Entrepreneurship, the ETH Zürich Stodola Medal, Blaise Pascal Medal in Biomedical Engineering − European Academy of Sciences, and the Shannon Director's Award of the National Institutes of Health.
A national search will be conducted for Mauro’s replacement, and until then, Dirk Sostman, M.D. will serve as president of the Institute for Academic Medicine. Ed Jones will continue his role as president and CEO of the RI and will work closely with Dirk. The Office of Technology Transfer will report to Mick Cantu.
We wish Mauro the very best on his next adventure. We will use what he built as a foundation to keep the RI growing in size and in importance—to continue Leading Medicine.